Navigation Links
Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
Date:7/30/2009

LAVAL, QC, July 30 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that James R. Howard-Tripp, Chief Executive Officer of the Company, will present at the Canaccord Adams 29th Annual Global Growth Conference at the InterContinental Boston, on Tuesday, August 11, 2009 at 3:30 p.m. ET.

Interested parties may access the live webcast for this presentation by visiting the "Events" section of the homepage of the Company's website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
2. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
3. Labopharm amends debt facility agreement with Hercules
4. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
5. Labopharm Reports Results for First Quarter Fiscal 2009
6. Labopharm announces details for first quarter results conference call and annual meeting
7. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
8. Labopharm to present at Cowen 29th Annual Health Care Conference
9. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
10. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
11. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths ... Assembly Bill (AB) 1512, which proposes a tax on prescription opioids to fund ...
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
Breaking Medicine Technology: